Search results (190)
« Back to NewsFirst new treatment for asthma attacks in 50 years
2 December 2024
An injection given during some asthma and chronic obstructive pulmonary disease (COPD) attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30 percent.
Reconstructing a lifetime of flu infections to understand long-term trends
8 November 2024
Using antibody data and mathematical modelling, a new study from researchers at the Pandemic Sciences Institute estimates annual patterns of influenza infection and protection over the past fifty years.
Launch of 'To Immunity and Beyond' podcast series
7 November 2024
Study maps out next generation of drug targets in autoimmune diseases
24 October 2024
In a world first, researchers at the Kennedy Institute of Rheumatology and the Nuffield Department of Medicine have mapped the cellular dynamics following treatment with the most commonly used advanced therapy in autoimmune diseases. They have discovered why some patients benefit from this therapy while others do not, potentially paving the way for new therapies.
Professor Ahmed Awarded Funding To Create World’s First Ovarian Cancer Prevention Vaccine
4 October 2024
Researchers at the MRC WIMM have been awarded up to £600,000 from Cancer Research UK (CRUK) to create the world’s first vaccine to prevent ovarian cancer.
New point-of-care testing to improve antibiotic use in Vietnam
24 September 2024
High levels of acceptability for a point-of-care testing service to improve antibiotic distribution for in Vietnamese pharmacies have been discovered by the Oxford University Clinical Research Unit (OUCRU), part of the Nuffield Department of Medicine.
Improving understanding of lung microbiome in severe asthma patients
12 September 2024
Researchers in the Nuffield Department of Medicine, supported by NIHR Oxford Biomedical Research Centre (BRC), have discovered a link between potentially pathogenic bacteria and airways inflammation in people with severe asthma.
Developing the first cancer prevention vaccine for Lynch syndrome
10 September 2024
Scientists from the Centre for Human Genetics at Nuffield Department of Medicine are taking the initial steps in developing the UK’s first vaccine to prevent cancer in people with Lynch syndrome, thanks to funding from Cancer Research UK.
Adoptive T cell therapy shows an enhanced tumour response
9 September 2024
The Van den Eynde groups at the Ludwig Institute for Cancer Research in Brussels and Oxford have demonstrated that deletion of PHD2/3 enzymes in CD8 T cells shows an enhanced tumour response in various cancer models.
Preventive vaccination could be a key strategy against Lassa fever
29 August 2024
Researchers at the University of Oxford and the University of Liverpool have for the first time been able to estimate the current burden of Lassa fever, project the impacts of a Lassa fever vaccination programme, and demonstrate how it may help avoid the next pandemic.
OUCRU and Universitas Indonesia complete historic malaria vaccine trial
19 August 2024
The Faculty of Medicine Universitas Indonesia (FMUI) and OUCRU Indonesia have completed a phase 2 clinical trial for two new malaria vaccines developed by Sanaria Inc. This is the first malaria vaccine trial ever conducted in Indonesia and the first in the Asia-Pacific region in over 30 years.
Structure of a key “trigger” of the immune response solved
15 August 2024
New research identifies autoimmunity against a key anti-inflammatory regulator
4 August 2024
A ground-breaking study, published by the New England Journal of Medicine, has identified a new disease-inducing mechanism for inflammatory bowel disease (IBD) in which the immune system attacks its own regulatory function.
ORTU awarded £2.8m to study treatment for pleural infection
23 July 2024
The Oxford Respiratory Trials Unit (ORTU) at the Nuffield Department of Medicine has been awarded a £2.8 million grant from the National Institute for Health and Care Research Health Technology Assessment (NIHR HTA) to conduct the MIST4 study.
Policy changes needed as drug-resistant malaria spreads in East Africa
22 July 2024
The efficacy of artemisinin derivatives, the cornerstone of current treatments for malaria, is being compromised in Africa where over 1,000 children are estimated to die each day from the disease. The spread of artemisinin-resistant malaria parasites across East Africa and beyond could result in millions more deaths without immediate health policy changes, warn experts in a paper published in Science.
Community voices shaping tuberculosis research in Viet Nam
19 July 2024
A recent publication by OUCRU researchers, published in the journal Public Health Action, highlights the importance of community engagement in TB research.
New Oxford Immunology Spin-out Company working to Improve Immunotherapy: MatchBio
18 July 2024
Oxford immunologists Professor Omer Dushek and Professor Anton van der Merwe have founded a new company called MatchBio, which aims to apply a range of approaches to make CAR T therapy more effective.
Yellowstone Biosciences spinout launches to advance cutting-edge cancer therapies
15 July 2024
Yellowstone Biosciences, a biotechnology spinout, has launched to pioneer new cancer treatments using advanced T-cell therapies based on groundbreaking research from the MRC Weatherall Institute of Molecular Medicine at the University of Oxford.
Côte d’Ivoire makes history as first nation to deploy R21/Matrix-M™ Malaria Vaccine
15 July 2024
Today marks the official rollout of the new R21/Matrix-M™ malaria vaccine - co-developed by the University of Oxford and Serum Institute of India, leveraging Novavax’s Matrix-M™ adjuvant technology. In a historic step in the battle to beat malaria, the first official vaccination is due to take place in Abidjan, Côte d’Ivoire, this morning and will be subsequently rolled-out in 38 districts across the country.
Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus
12 July 2024
Scientists at the University of Oxford have launched a new clinical trial to test a vaccine to protect people against deadly Marburg virus.